# NEXT (NCT03171025)

> Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab
- Indication: localized muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03171025
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Utah
- Conditions: Bladder Cancer
- Interventions: Nivolumab
- Enrollment: 200
- Primary outcome: Two-year rate of failure-free survival (FFS)

## Indexed commentary on NEXT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 9
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=next-nct03171025

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03171025", "email": "<work email>"}; the inbox owner confirms by the emailed link.